The efficacy of chemotherapy re-challenge in third-line setting for metastatic colorectal cancer patients: a real-world study.
10.3760/cma.j.cn112152-20220901-00591
- Author:
Jing Jing DUAN
1
;
Tao NING
1
;
Ming BAI
1
;
Le ZHANG
1
;
Hong Li LI
1
;
Rui LIU
1
;
Shao Hua GE
1
;
Xia WANG
1
;
Yu Chong YANG
1
;
Zhi JI
1
;
Fei Xue WANG
1
;
Yan Sha SUN
1
;
Yi BA
1
;
Ting DENG
1
Author Information
1. Department of GI Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
- Publication Type:Journal Article
- Keywords:
Chemotherapy re-challenge;
Colorectal neoplasms;
Third-line chemotherapy
- MeSH:
Humans;
Irinotecan/therapeutic use*;
Oxaliplatin/therapeutic use*;
Colorectal Neoplasms/pathology*;
Retrospective Studies;
Fluorouracil;
Colonic Neoplasms/chemically induced*;
Rectal Neoplasms/drug therapy*;
Antineoplastic Combined Chemotherapy Protocols/adverse effects*;
Camptothecin/adverse effects*
- From:
Chinese Journal of Oncology
2023;45(11):967-972
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the efficacy of chemotherapy re-challenge in the third-line setting for patients with metastatic colorectal cancer (mCRC) in the real world. Methods: The clinicopathological data, treatment information, recent treatment efficacy, adverse events and survival data of mCRC patients who had disease progression after treatment with oxaliplatin-based and/or irinotecan-based chemotherapy and received third-line chemotherapy re-challenge from January 2013 to December 2020 at Tianjin Medical University Cancer Institute and Hospital were retrospectively collected. Survival curves were plotted with the Kaplan-Meier method, and the Cox proportional hazard model was used to analyze the prognostic factors. Results: A total of 95 mCRC patients were included. Among them, 32 patients (33.7%) received chemotherapy alone and 63 patients (66.3%) received chemotherapy combined with targeted drugs. Eighty-three patients were treated with dual-drug chemotherapy (87.4%), including oxaliplatin re-challenge in 35 patients and irinotecan re-challenge in 48 patients. The remaining 12 patients were treated with triplet chemotherapy regimens (12.6%). Among them, as 5 patients had sequential application of oxaliplatin and irinotecan in front-line treatments, their third-line therapy re-challenged both oxaliplatin and irinotecan; 7 patients only had oxaliplatin prescription before, and these patients re-challenged oxaliplatin in the third-line treatment. The overall response rate (ORR) and disease control rate (DCR) reached 8.6% (8/93) and 61.3% (57/93), respectively. The median progression free survival (mPFS) and median overall survival (mOS) were 4.9 months and 13.0 months, respectively. The most common adverse events were leukopenia (34.7%) and neutropenia (34.7%), followed by gastrointestinal adverse reactions such as nausea (32.6%) and vomiting (31.6%). Grade 3-4 adverse events were mostly hematological toxicity. Cox multivariate analysis showed that gender (HR=1.609, 95% CI: 1.016-2.548) and the PFS of front-line treatments (HR=0.598, 95% CI: 0.378-0.947) were independent prognostic factors. Conclusion: The results suggested that it is safe and effective for mCRC patients to choose third-line chemotherapy re-challenge, especially for patients with a PFS of more than one year in front-line treatments.
